Doxorubicin and cyclophosphamide mode of chemotherapy–related cardiomyopathy: Review of preclinical model

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Current Problems in Cardiology Pub Date : 2024-10-19 DOI:10.1016/j.cpcardiol.2024.102882

Ashot Avagimyan , Lev Kakturskiy , Nana Pogosova , Giulia Ottaviani , Manfredi Rizzo , Nizal Sarrafzadegan

{"title":"Doxorubicin and cyclophosphamide mode of chemotherapy–related cardiomyopathy: Review of preclinical model","authors":"Ashot Avagimyan , Lev Kakturskiy , Nana Pogosova , Giulia Ottaviani , Manfredi Rizzo , Nizal Sarrafzadegan","doi":"10.1016/j.cpcardiol.2024.102882","DOIUrl":null,"url":null,"abstract":"<div><div>Over the past 70 years, there has been extensive research focused on preventing chemotherapy-related cardiovascular complications. However, the current state of cardio-oncology research has raised more questions than answers. Experimental studies often present data that are difficult to compare and, at times, contradictory. One notable limitation in translating experimental findings to clinical practice is the reliance on models that administer only one chemotherapeutic drug to experimental animals, despite the common use of multidrug cancer treatments in real clinical settings. This article aims to discuss our own experience in modeling an experimental rat model of cardiomyopathy induced by the administration of two chemotherapeutic drugs, doxorubicin (adriamycin) and cyclophosphamide (AC mode of chemotherapy) – Avagimyan A., et al model, along with a subsequent review of morphological changes based on our personal archive.<ul><li><span>1.</span><span><div>AC - Doxorubicin (Adriamycin) + Cyclophosphamide</div></span></li><li><span>2.</span><span><div>CaMKII - Calcium/Calmodulin-dependent protein kinase II</div></span></li><li><span>3.</span><span><div>Circ-INSR - Circulating Insulin Receptor</div></span></li><li><span>4.</span><span><div>CVDs - Cardiovascular Diseases</div></span></li><li><span>5.</span><span><div>CP – Cardioprotector</div></span></li><li><span>6.</span><span><div>GLUT - Glucose Transporter</div></span></li><li><span>7.</span><span><div>HF – Heart Failure</div></span></li><li><span>8.</span><span><div>ICAM - Intercellular Adhesion Molecule</div></span></li><li><span>9.</span><span><div>IL - Interleukin</div></span></li><li><span>10.</span><span><div>IκBα - Inhibitor of kappa B alpha</div></span></li><li><span>11.</span><span><div>MMP - Matrix Metalloproteinase</div></span></li><li><span>12.</span><span><div>MyD88 - Myeloid Differentiation Primary Response 88</div></span></li><li><span>13.</span><span><div>NADP+ - Nicotinamide Adenine Dinucleotide Phosphate</div></span></li><li><span>14.</span><span><div>NADPH - Nicotinamide Adenine Dinucleotide Phosphate Hydrogen</div></span></li><li><span>15.</span><span><div>NF-κB - Nuclear Factor kappa B</div></span></li><li><span>16.</span><span><div>NLRP3 - Nucleotide-binding domain, leucine-rich repeat containing protein 3</div></span></li><li><span>17.</span><span><div>NOS - Nitric Oxide Synthase</div></span></li><li><span>18.</span><span><div>Nrf2 - Nuclear factor erythroid 2-related factor 2</div></span></li><li><span>19.</span><span><div>NT-proBNP - N-terminal pro-B-type natriuretic peptide</div></span></li><li><span>20.</span><span><div>PLN - Phospholamban</div></span></li><li><span>21.</span><span><div>RyR - Ryanodine receptor</div></span></li><li><span>22.</span><span><div>SERCA2a - Sarco/Endoplasmic Reticulum Calcium ATPase 2a</div></span></li><li><span>23.</span><span><div>Sirt3 - Sirtuin 3</div></span></li><li><span>24.</span><span><div>SMAD3 - Mothers Against Decapentaplegic Homolog 3</div></span></li><li><span>25.</span><span><div>TGF-β1 - Transforming Growth Factor beta 1</div></span></li><li><span>26.</span><span><div>TLR4 - Toll-like receptor 4</div></span></li><li><span>27.</span><span><div>TNF-α - Tumor Necrosis Factor alpha</div></span></li><li><span>28.</span><span><div>VCAM - Vascular Cell Adhesion Molecule</div></span></li></ul></div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 1","pages":"Article 102882"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0146280624005176","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Over the past 70 years, there has been extensive research focused on preventing chemotherapy-related cardiovascular complications. However, the current state of cardio-oncology research has raised more questions than answers. Experimental studies often present data that are difficult to compare and, at times, contradictory. One notable limitation in translating experimental findings to clinical practice is the reliance on models that administer only one chemotherapeutic drug to experimental animals, despite the common use of multidrug cancer treatments in real clinical settings. This article aims to discuss our own experience in modeling an experimental rat model of cardiomyopathy induced by the administration of two chemotherapeutic drugs, doxorubicin (adriamycin) and cyclophosphamide (AC mode of chemotherapy) – Avagimyan A., et al model, along with a subsequent review of morphological changes based on our personal archive.

1.
AC - Doxorubicin (Adriamycin) + Cyclophosphamide
2.
CaMKII - Calcium/Calmodulin-dependent protein kinase II
3.
Circ-INSR - Circulating Insulin Receptor
4.
CVDs - Cardiovascular Diseases
5.
CP – Cardioprotector
6.
GLUT - Glucose Transporter
7.
HF – Heart Failure
8.
ICAM - Intercellular Adhesion Molecule
9.
IL - Interleukin
10.
IκBα - Inhibitor of kappa B alpha
11.
MMP - Matrix Metalloproteinase
12.
MyD88 - Myeloid Differentiation Primary Response 88
13.
NADP+ - Nicotinamide Adenine Dinucleotide Phosphate
14.
NADPH - Nicotinamide Adenine Dinucleotide Phosphate Hydrogen
15.
NF-κB - Nuclear Factor kappa B
16.
NLRP3 - Nucleotide-binding domain, leucine-rich repeat containing protein 3
17.
NOS - Nitric Oxide Synthase
18.
Nrf2 - Nuclear factor erythroid 2-related factor 2
19.
NT-proBNP - N-terminal pro-B-type natriuretic peptide
20.
PLN - Phospholamban
21.
RyR - Ryanodine receptor
22.
SERCA2a - Sarco/Endoplasmic Reticulum Calcium ATPase 2a
23.
Sirt3 - Sirtuin 3
24.
SMAD3 - Mothers Against Decapentaplegic Homolog 3
25.
TGF-β1 - Transforming Growth Factor beta 1
26.
TLR4 - Toll-like receptor 4
27.
TNF-α - Tumor Necrosis Factor alpha
28.
VCAM - Vascular Cell Adhesion Molecule

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多柔比星和环磷酰胺的化疗相关心肌病模式：临床前模型回顾。

在过去的 70 年中，人们对预防化疗相关心血管并发症进行了广泛的研究。然而，心血管肿瘤学研究的现状是问题多于答案。实验研究中的数据往往难以比较，有时甚至相互矛盾。将实验结果转化为临床实践的一个显著局限是，尽管在实际临床环境中普遍使用多种药物治疗癌症，但实验动物却只能依赖于使用一种化疗药物的模型。本文旨在讨论我们自己在建立由两种化疗药物多柔比星（阿霉素）和环磷酰胺（AC 化疗模式）诱导的心肌病实验大鼠模型方面的经验--Avagimyan A. 等人的模型，以及随后根据我们的个人档案对形态学变化的回顾。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Problems in Cardiology 医学-心血管系统

CiteScore

4.80

自引率

2.40%

发文量

392

审稿时长

6 days

期刊介绍： Under the editorial leadership of noted cardiologist Dr. Hector O. Ventura, Current Problems in Cardiology provides focused, comprehensive coverage of important clinical topics in cardiology. Each monthly issues, addresses a selected clinical problem or condition, including pathophysiology, invasive and noninvasive diagnosis, drug therapy, surgical management, and rehabilitation; or explores the clinical applications of a diagnostic modality or a particular category of drugs. Critical commentary from the distinguished editorial board accompanies each monograph, providing readers with additional insights. An extensive bibliography in each issue saves hours of library research.